CZ20023948A3 - Sloučeniny vhodné k přípravě léčiv s inhibičními účinky na fosfodiesterázu IV - Google Patents
Sloučeniny vhodné k přípravě léčiv s inhibičními účinky na fosfodiesterázu IV Download PDFInfo
- Publication number
- CZ20023948A3 CZ20023948A3 CZ20023948A CZ20023948A CZ20023948A3 CZ 20023948 A3 CZ20023948 A3 CZ 20023948A3 CZ 20023948 A CZ20023948 A CZ 20023948A CZ 20023948 A CZ20023948 A CZ 20023948A CZ 20023948 A3 CZ20023948 A3 CZ 20023948A3
- Authority
- CZ
- Czechia
- Prior art keywords
- methoxyphenyl
- compounds according
- compounds
- acid
- alkoxy
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 69
- 239000003814 drug Substances 0.000 title claims abstract description 14
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 title claims description 11
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 title claims description 11
- 230000005764 inhibitory process Effects 0.000 title description 6
- 230000000694 effects Effects 0.000 title description 4
- 230000001747 exhibiting effect Effects 0.000 title 1
- 238000002360 preparation method Methods 0.000 claims abstract description 32
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 12
- 229910052736 halogen Inorganic materials 0.000 claims abstract description 10
- 150000002367 halogens Chemical class 0.000 claims abstract description 9
- 125000000000 cycloalkoxy group Chemical group 0.000 claims abstract description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 5
- 125000001589 carboacyl group Chemical group 0.000 claims abstract description 3
- 239000000203 mixture Substances 0.000 claims description 10
- VSDJNOSLKMYOSJ-UHFFFAOYSA-N 4-(3-cyclopentyloxy-4-methoxyphenyl)-4-oxobutanoic acid Chemical compound COC1=CC=C(C(=O)CCC(O)=O)C=C1OC1CCCC1 VSDJNOSLKMYOSJ-UHFFFAOYSA-N 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 208000006673 asthma Diseases 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- INNDKEFLWYGZFG-VIFPVBQESA-N (2s)-2-amino-4-(3-fluoro-4-methoxyphenyl)-n-hydroxybutanamide Chemical compound COC1=CC=C(CC[C@H](N)C(=O)NO)C=C1F INNDKEFLWYGZFG-VIFPVBQESA-N 0.000 claims description 3
- OAQPEPHQTOIVEK-UKTHLTGXSA-N (e)-4-(3-cyclopentyloxy-4-methoxyphenyl)-3-methoxycarbonylbut-3-enoic acid Chemical compound COC(=O)C(\CC(O)=O)=C\C1=CC=C(OC)C(OC2CCCC2)=C1 OAQPEPHQTOIVEK-UKTHLTGXSA-N 0.000 claims description 3
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims description 3
- 206010040070 Septic Shock Diseases 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 230000036303 septic shock Effects 0.000 claims description 3
- XBIAKZYGVXKYHN-QMMMGPOBSA-N (2s)-4-(3-fluoro-4-methoxyphenyl)-4-oxo-2-[(2,2,2-trifluoroacetyl)amino]butanoic acid Chemical compound COC1=CC=C(C(=O)C[C@H](NC(=O)C(F)(F)F)C(O)=O)C=C1F XBIAKZYGVXKYHN-QMMMGPOBSA-N 0.000 claims description 2
- JQXWKRLBRLHLES-SDNWHVSQSA-N (e)-5-(3-cyclopentyloxy-4-methoxyphenyl)-4-methoxycarbonylpent-4-enoic acid Chemical compound OC(=O)CC/C(C(=O)OC)=C\C1=CC=C(OC)C(OC2CCCC2)=C1 JQXWKRLBRLHLES-SDNWHVSQSA-N 0.000 claims description 2
- XIYMYAFRUIHUMK-UHFFFAOYSA-N 4-(3-fluoro-4-methoxyphenyl)-2-[(2,2,2-trifluoroacetyl)amino]butanoic acid Chemical compound COC1=CC=C(CCC(NC(=O)C(F)(F)F)C(O)=O)C=C1F XIYMYAFRUIHUMK-UHFFFAOYSA-N 0.000 claims description 2
- XBIAKZYGVXKYHN-UHFFFAOYSA-N 4-(3-fluoro-4-methoxyphenyl)-4-oxo-2-[(2,2,2-trifluoroacetyl)amino]butanoic acid Chemical compound COC1=CC=C(C(=O)CC(NC(=O)C(F)(F)F)C(O)=O)C=C1F XBIAKZYGVXKYHN-UHFFFAOYSA-N 0.000 claims description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 11
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 abstract description 9
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 abstract description 6
- -1 R5 is H Chemical group 0.000 abstract description 4
- 125000000217 alkyl group Chemical group 0.000 abstract description 2
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 239000000047 product Substances 0.000 description 32
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 30
- 239000000243 solution Substances 0.000 description 30
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 26
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 26
- 238000003756 stirring Methods 0.000 description 24
- 238000005160 1H NMR spectroscopy Methods 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 239000007787 solid Substances 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 10
- 238000001816 cooling Methods 0.000 description 10
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 10
- QDQAXSGZAIUCQW-UHFFFAOYSA-N 3-(2,3-dihydroindol-1-yl)propanoic acid Chemical compound C1=CC=C2N(CCC(=O)O)CCC2=C1 QDQAXSGZAIUCQW-UHFFFAOYSA-N 0.000 description 9
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 9
- 235000019439 ethyl acetate Nutrition 0.000 description 9
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 8
- 239000004480 active ingredient Substances 0.000 description 7
- 125000000896 monocarboxylic acid group Chemical group 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 125000001887 cyclopentyloxy group Chemical group C1(CCCC1)O* 0.000 description 6
- 229950005741 rolipram Drugs 0.000 description 6
- 239000012043 crude product Substances 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 239000002244 precipitate Substances 0.000 description 5
- HJORMJIFDVBMOB-UHFFFAOYSA-N rolipram Chemical compound COC1=CC=C(C2CC(=O)NC2)C=C1OC1CCCC1 HJORMJIFDVBMOB-UHFFFAOYSA-N 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 4
- JIXDOBAQOWOUPA-UHFFFAOYSA-N 1-fluoro-2-methoxybenzene Chemical compound COC1=CC=CC=C1F JIXDOBAQOWOUPA-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 3
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 238000010907 mechanical stirring Methods 0.000 description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 3
- ABTJOHYOWBAGTP-REOHCLBHSA-N n-[(3s)-2,5-dioxooxolan-3-yl]-2,2,2-trifluoroacetamide Chemical compound FC(F)(F)C(=O)N[C@H]1CC(=O)OC1=O ABTJOHYOWBAGTP-REOHCLBHSA-N 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- ABDKAPXRBAPSQN-UHFFFAOYSA-N veratrole Chemical compound COC1=CC=CC=C1OC ABDKAPXRBAPSQN-UHFFFAOYSA-N 0.000 description 3
- WUDVONGUDMDEBQ-VIFPVBQESA-N (2s)-2-amino-4-(3-fluoro-4-methoxyphenyl)butanoic acid Chemical compound COC1=CC=C(CC[C@H](N)C(O)=O)C=C1F WUDVONGUDMDEBQ-VIFPVBQESA-N 0.000 description 2
- FZFWPURYSWKIRT-UHFFFAOYSA-N 3-cyclopentyloxy-4-methoxybenzaldehyde Chemical compound COC1=CC=C(C=O)C=C1OC1CCCC1 FZFWPURYSWKIRT-UHFFFAOYSA-N 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- 150000001555 benzenes Chemical group 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 239000012141 concentrate Substances 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- NRNYHSBGWFIHAJ-GXDHUFHOSA-N dimethyl (2e)-2-[(3-cyclopentyloxy-4-methoxyphenyl)methylidene]butanedioate Chemical compound COC(=O)C\C(C(=O)OC)=C/C1=CC=C(OC)C(OC2CCCC2)=C1 NRNYHSBGWFIHAJ-GXDHUFHOSA-N 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000002158 endotoxin Substances 0.000 description 2
- 150000002170 ethers Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- 229920006008 lipopolysaccharide Polymers 0.000 description 2
- 239000012452 mother liquor Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 239000012047 saturated solution Substances 0.000 description 2
- 239000007790 solid phase Substances 0.000 description 2
- 239000011877 solvent mixture Substances 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LCGFVWKNXLRFIF-UHFFFAOYSA-N 1,2,3,4-tetrahydronaphthalen-2-amine Chemical class C1=CC=C2CC(N)CCC2=C1 LCGFVWKNXLRFIF-UHFFFAOYSA-N 0.000 description 1
- GHKFGRVGAQYZNT-UHFFFAOYSA-N 1,2-dibutoxybenzene Chemical compound CCCCOC1=CC=CC=C1OCCCC GHKFGRVGAQYZNT-UHFFFAOYSA-N 0.000 description 1
- YWBDMYUZGIIBJY-UHFFFAOYSA-N 1,2-dicyclohexyloxybenzene Chemical compound C1CCCCC1OC1=CC=CC=C1OC1CCCCC1 YWBDMYUZGIIBJY-UHFFFAOYSA-N 0.000 description 1
- RDZWPRPZGZDHHM-UHFFFAOYSA-N 1,2-dicyclopentyloxybenzene Chemical compound C1CCCC1OC1=CC=CC=C1OC1CCCC1 RDZWPRPZGZDHHM-UHFFFAOYSA-N 0.000 description 1
- QZYDOKBVZJLQCK-UHFFFAOYSA-N 1,2-diethoxybenzene Chemical compound CCOC1=CC=CC=C1OCC QZYDOKBVZJLQCK-UHFFFAOYSA-N 0.000 description 1
- XUIKECLBCZBUCM-UHFFFAOYSA-N 1,2-dipropoxybenzene Chemical compound CCCOC1=CC=CC=C1OCCC XUIKECLBCZBUCM-UHFFFAOYSA-N 0.000 description 1
- HTDQSWDEWGSAMN-UHFFFAOYSA-N 1-bromo-2-methoxybenzene Chemical compound COC1=CC=CC=C1Br HTDQSWDEWGSAMN-UHFFFAOYSA-N 0.000 description 1
- QGRPVMLBTFGQDQ-UHFFFAOYSA-N 1-chloro-2-methoxybenzene Chemical compound COC1=CC=CC=C1Cl QGRPVMLBTFGQDQ-UHFFFAOYSA-N 0.000 description 1
- DVQWNQBEUKXONL-UHFFFAOYSA-N 1-iodo-2-methoxybenzene Chemical compound COC1=CC=CC=C1I DVQWNQBEUKXONL-UHFFFAOYSA-N 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- VADKRMSMGWJZCF-UHFFFAOYSA-N 2-bromophenol Chemical compound OC1=CC=CC=C1Br VADKRMSMGWJZCF-UHFFFAOYSA-N 0.000 description 1
- ISPYQTSUDJAMAB-UHFFFAOYSA-N 2-chlorophenol Chemical compound OC1=CC=CC=C1Cl ISPYQTSUDJAMAB-UHFFFAOYSA-N 0.000 description 1
- HFHFGHLXUCOHLN-UHFFFAOYSA-N 2-fluorophenol Chemical compound OC1=CC=CC=C1F HFHFGHLXUCOHLN-UHFFFAOYSA-N 0.000 description 1
- KQDJTBPASNJQFQ-UHFFFAOYSA-N 2-iodophenol Chemical compound OC1=CC=CC=C1I KQDJTBPASNJQFQ-UHFFFAOYSA-N 0.000 description 1
- 241000819038 Chichester Species 0.000 description 1
- 101100135868 Dictyostelium discoideum pde3 gene Proteins 0.000 description 1
- 101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 description 1
- 101100351286 Dictyostelium discoideum pdeE gene Proteins 0.000 description 1
- 101100135859 Dictyostelium discoideum regA gene Proteins 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- MUXOBHXGJLMRAB-UHFFFAOYSA-N Dimethyl succinate Chemical compound COC(=O)CCC(=O)OC MUXOBHXGJLMRAB-UHFFFAOYSA-N 0.000 description 1
- 101001117089 Drosophila melanogaster Calcium/calmodulin-dependent 3',5'-cyclic nucleotide phosphodiesterase 1 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101000909851 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) cAMP/cGMP dual specificity phosphodiesterase Rv0805 Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101150098694 PDE5A gene Proteins 0.000 description 1
- 101100082606 Plasmodium falciparum (isolate 3D7) PDEbeta gene Proteins 0.000 description 1
- 208000018569 Respiratory Tract disease Diseases 0.000 description 1
- 101100135860 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) PDE2 gene Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 description 1
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- XTDYIOOONNVFMA-UHFFFAOYSA-N dimethyl pentanedioate Chemical compound COC(=O)CCCC(=O)OC XTDYIOOONNVFMA-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- ZLZDWZHTRLIWOY-UKTHLTGXSA-N methyl (2e)-2-[(3-cyclopentyloxy-4-methoxyphenyl)methylidene]-4-(hydroxyamino)-4-oxobutanoate Chemical compound ONC(=O)C/C(C(=O)OC)=C\C1=CC=C(OC)C(OC2CCCC2)=C1 ZLZDWZHTRLIWOY-UKTHLTGXSA-N 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000001338 necrotic effect Effects 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 101150037969 pde-6 gene Proteins 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 238000007738 vacuum evaporation Methods 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/40—Unsaturated compounds
- C07C59/76—Unsaturated compounds containing keto groups
- C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
- C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
- C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
- C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
- C07C69/734—Ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/09—Geometrical isomers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT2000RM000341A IT1317049B1 (it) | 2000-06-23 | 2000-06-23 | Composti utili per la preparazione di medicamenti ad attivita'inibitrice della fosfodiesterasi iv. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CZ20023948A3 true CZ20023948A3 (cs) | 2003-04-16 |
Family
ID=11454800
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CZ20023948A CZ20023948A3 (cs) | 2000-06-23 | 2001-06-15 | Sloučeniny vhodné k přípravě léčiv s inhibičními účinky na fosfodiesterázu IV |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7169808B2 (enExample) |
| EP (1) | EP1292563A2 (enExample) |
| JP (1) | JP2004501888A (enExample) |
| KR (1) | KR100764885B1 (enExample) |
| AU (1) | AU2001269420A1 (enExample) |
| CA (1) | CA2411162A1 (enExample) |
| CZ (1) | CZ20023948A3 (enExample) |
| HU (2) | HUP0301205A3 (enExample) |
| IT (1) | IT1317049B1 (enExample) |
| MX (1) | MXPA02012589A (enExample) |
| PL (1) | PL359409A1 (enExample) |
| SK (1) | SK17302002A3 (enExample) |
| WO (1) | WO2002000593A2 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7842727B2 (en) | 2001-03-27 | 2010-11-30 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors |
| US7312247B2 (en) | 2001-03-27 | 2007-12-25 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors |
| US8026280B2 (en) * | 2001-03-27 | 2011-09-27 | Errant Gene Therapeutics, Llc | Histone deacetylase inhibitors |
| EP1511477A4 (en) | 2002-05-22 | 2008-04-09 | Errant Gene Therapeutics Llc | HISTONE DEACETYLASE INHIBITORS BASED ON ALPHA-KETO-EPOXYDE COMPOUNDS |
| JP2006508986A (ja) * | 2002-11-20 | 2006-03-16 | エルラント ゲネ セラペウチクス エルエルシー | ヒストンデアセチラーゼ阻害剤による肺細胞の治療方法 |
| WO2005073180A1 (ja) * | 2003-12-25 | 2005-08-11 | Kureha Corporation | ヒドロキサム酸誘導体、及び該誘導体を含むａｇｅ生成阻害剤 |
| GB0818907D0 (en) * | 2008-10-15 | 2008-11-19 | Isis Innovation | Histone lysine demethylase inhibitors |
| EP3691634A4 (en) | 2017-10-05 | 2021-03-31 | Biogen Inc. | PROCESS FOR THE PREPARATION OF PYRROLIDINE ALPHA-CARBOXAMIDE DERIVATIVES |
| MX2021012421A (es) * | 2019-04-10 | 2022-02-10 | Biogen Inc | Procesos para preparar derivados de pirrolidina alfa-carboxamida. |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3714356A (en) * | 1971-01-18 | 1973-01-30 | Morton Norwich Products Inc | Antibacterial composition and method |
| GB1419968A (en) | 1972-12-21 | 1975-12-31 | Wyeth John & Brother Ltd | Aziridine derivatives |
| AU6889274A (en) * | 1973-05-17 | 1975-11-20 | Astra Laekemedel Ab | Treatment of neurological disorders |
| DE3160641D1 (en) * | 1980-05-13 | 1983-08-25 | Ciba Geigy Ag | Process for the preparation of benzene or naphthalene alkenyl carboxylic acid derivatives |
| US4820828A (en) * | 1987-03-04 | 1989-04-11 | Ortho Pharmaceutical Corporation | Cinnamohydroxamic acids |
| US4971959A (en) * | 1987-04-14 | 1990-11-20 | Warner-Lambert Company | Trisubstituted phenyl analogs having activity for congestive heart failure |
| US5232735A (en) * | 1990-06-01 | 1993-08-03 | Bioresearch, Inc. | Ingestibles containing substantially tasteless sweetness inhibitors as bitter taste reducers or substantially tasteless bitter inhibitors as sweet taste reducers |
| WO1992000968A1 (en) * | 1990-07-10 | 1992-01-23 | Smithkline Beecham Corporation | Oxamides |
| US5191084A (en) * | 1991-05-01 | 1993-03-02 | American Home Products Corporation | Phenyl pyrazolidinones as bronchodilators and anti-inflammatory agents |
| PT100441A (pt) * | 1991-05-02 | 1993-09-30 | Smithkline Beecham Corp | Pirrolidinonas, seu processo de preparacao, composicoes farmaceuticas que as contem e uso |
| US5665754A (en) | 1993-09-20 | 1997-09-09 | Glaxo Wellcome Inc. | Substituted pyrrolidines |
| EP0850215B1 (en) * | 1995-07-26 | 2000-10-18 | Pfizer Inc. | N-(aroyl)glycine hydroxamic acid derivatives and related compounds |
| CN1191528A (zh) * | 1995-07-26 | 1998-08-26 | 武田药品工业株式会社 | 具有褪黑激素受体结合亲合力的苯并环烯化合物,其生产方法和用途 |
| JP4017214B2 (ja) * | 1996-06-11 | 2007-12-05 | 興和創薬株式会社 | ５−フェニル−３−ピリダジノン誘導体 |
| FI990180A7 (fi) * | 1996-08-12 | 1999-03-08 | Celgene Corp | Uusia immunoterapeuttisia aineita ja niiden käyttö sytokiini-tasojen pienentämiseksi |
| GB9618349D0 (en) * | 1996-09-03 | 1996-10-16 | Pharmacia Spa | N-substituted 2-amino-4-phenyl-4-oxo-butanoic acid derivatives with kynurenine-3-hydroxylase inhibitory activity |
| AR017014A1 (es) | 1997-07-22 | 2001-08-22 | Astrazeneca Ab | Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos |
| IT1294931B1 (it) * | 1997-09-22 | 1999-04-23 | Sigma Tau Ind Farmaceuti | Derivati della 2-amminotetralina procedimento per la loro preparazione e composizioni farmaceutiche che li contengono, attive nella |
| EP1047425A4 (en) | 1997-12-17 | 2009-04-22 | Merck & Co Inc | INTEGRIN RECEPTOR ANTAGONISTS |
| US6028116A (en) * | 1998-04-03 | 2000-02-22 | Cell Pathways, Inc. | Substituted condensation products of 1H-indenyl-hydroxyalkanes with aldehydes for neoplasia |
| TR200101649T2 (tr) * | 1998-12-14 | 2001-10-22 | Fujisawa Pharmaceutical Co., Ltd. | Piperazin türevleri. |
| DE19952146A1 (de) * | 1999-10-29 | 2001-06-07 | Boehringer Ingelheim Pharma | Arylalkane, Arylalkene und Aryl-azaalkane, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
-
2000
- 2000-06-23 IT IT2000RM000341A patent/IT1317049B1/it active
-
2001
- 2001-06-15 SK SK1730-2002A patent/SK17302002A3/sk unknown
- 2001-06-15 CZ CZ20023948A patent/CZ20023948A3/cs unknown
- 2001-06-15 AU AU2001269420A patent/AU2001269420A1/en not_active Abandoned
- 2001-06-15 MX MXPA02012589A patent/MXPA02012589A/es active IP Right Grant
- 2001-06-15 KR KR1020027016531A patent/KR100764885B1/ko not_active Expired - Fee Related
- 2001-06-15 HU HU0301205A patent/HUP0301205A3/hu unknown
- 2001-06-15 JP JP2002505343A patent/JP2004501888A/ja active Pending
- 2001-06-15 PL PL01359409A patent/PL359409A1/xx not_active Application Discontinuation
- 2001-06-15 HU HU0303399A patent/HUP0303399A3/hu unknown
- 2001-06-15 WO PCT/IT2001/000312 patent/WO2002000593A2/en not_active Ceased
- 2001-06-15 CA CA002411162A patent/CA2411162A1/en not_active Abandoned
- 2001-06-15 EP EP01947782A patent/EP1292563A2/en not_active Withdrawn
- 2001-06-15 US US10/311,756 patent/US7169808B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| ITRM20000341A1 (it) | 2001-12-23 |
| MXPA02012589A (es) | 2003-05-14 |
| HUP0303399A3 (en) | 2004-10-28 |
| KR20030012870A (ko) | 2003-02-12 |
| WO2002000593A3 (en) | 2002-05-16 |
| HUP0301205A3 (en) | 2004-03-01 |
| PL359409A1 (en) | 2004-08-23 |
| WO2002000593A2 (en) | 2002-01-03 |
| US20030195257A1 (en) | 2003-10-16 |
| HUP0303399A2 (hu) | 2004-01-28 |
| JP2004501888A (ja) | 2004-01-22 |
| KR100764885B1 (ko) | 2007-10-09 |
| US7169808B2 (en) | 2007-01-30 |
| ITRM20000341A0 (it) | 2000-06-23 |
| SK17302002A3 (sk) | 2003-05-02 |
| CA2411162A1 (en) | 2002-01-03 |
| HUP0301205A2 (hu) | 2003-11-28 |
| EP1292563A2 (en) | 2003-03-19 |
| AU2001269420A1 (en) | 2002-01-08 |
| IT1317049B1 (it) | 2003-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100294381B1 (ko) | 헤테로아세트산유도체 | |
| EP2675771B1 (en) | 4-hydroxybutyric acid deuterated analogs | |
| CN105189438A (zh) | 用于治疗纤维化的经取代的芳族化合物及相关方法 | |
| FR2527204A1 (fr) | Nouveaux composes utiles comme medicaments anti-allergiques et procede et intermediaires pour leur separation | |
| KR100764885B1 (ko) | 포스포디에스테라제 ｉｖ 억제 활성을 갖는 약제의 제조에유용한 화합물 | |
| WO2019179494A1 (zh) | 取代的十五烷二酸化合物及药物组合物及其用途 | |
| EP0087378B1 (fr) | Ethers-oximes d'alcoylaminoalcools comme médicaments, produits nouveaux et procédés pour leur préparation | |
| EP0261017B1 (fr) | Esters d'aminoacides d'alcools cycloaliphatiques, procédé de préparation et utilisation comme médicaments | |
| JP2000506137A (ja) | アミノテトラリン誘導体及び組成物並びにその使用方法 | |
| US4461775A (en) | Hydroxythioether fatty acid derivatives | |
| WO1999011625A1 (en) | Huperzine a derivatives | |
| US10843993B2 (en) | Deuterated idebenone | |
| CN115583890B (zh) | 一种治疗血脂异常的药物及其用途 | |
| FR2864535A1 (fr) | Derives acides de quinoline et leurs applications en therapeutique | |
| JPH05105627A (ja) | 腸機能性疾患の治療に用いられる新規な医薬組成物と、その調整方法と、治療用医薬の調製方法 | |
| CS208752B2 (en) | Method of making the r-n-(2-fenyl-2-hydroxyethyl)-3-fenyl propylamines | |
| EP0863866A1 (en) | Butyrate prodrugs of lactic acid | |
| US4146728A (en) | Esters of 2-[4-(4-chlorobenzoyl)-phenoxy-2-methyl-propionic acid with bis-(hydroxyalkylthio)-alkanes | |
| JP2006510688A (ja) | 新規アミノベンゾフェノン化合物 | |
| WO2002000609A2 (en) | 2,6,7-substituted tetralines useful for the preparation of medicaments with phosphodiesterase iv inhibitory activity | |
| WO1996016017A1 (en) | Novel arylpropionic derivatives with analgesic action and the process for the preparation thereof | |
| HK1196597A1 (zh) | 用於治疗炎性肠病的茚衍生物 | |
| HK1196597B (en) | Indene derivatives for use in the treatment of inflammatory bowel disease | |
| AU2014200986A1 (en) | 4-hydroxybutyric acid analogs | |
| HK1195054B (en) | 4-hydroxybutyric acid deuterated analogs |